[ad_1]
Boston, April 17, 2023 /PRNewswire/ — Sapphiros, a platform company to build the next generation of consumer diagnostic technologies, is proud to announce that it has been selected by the National Institutes of Health (NIH) for Rapid Diagnostics (RADx).®) to develop a high-throughput, over-the-counter (OTC), molecular multiplex respiratory diagnostic test that can rapidly detect RSV, influenza A, influenza B, and Covid-19 in a single assay.
Safiros was awarded $11.1 million To deliver the first work program that combines proprietary isothermal molecular chemistry and proprietary high-volume, reel-to-reel conductive ink, printed electronics and sensing technologies. These features are designed to provide low-cost, easy-to-use, and rapidly deployable diagnostic tests. Once this initial work program is successfully completed, Saphiros will explore additional support and funding.
“This is a major milestone for our company and further validates Sapiro’s unique and transformative technologies, which when combined will create one of the most innovative diagnostic products. We are honored to have played a major role in developing a platform that will have an immediate impact. It will improve patient outcomes and reduce healthcare costs in the future through biosecurity concerns and Epidemics allow for rapid response,” he said. Mark GladwellCEO of Safiros.
This project was supported in part by federal funds from the National Institute for Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health, Department of Health and Human Services, under contract number 75N92023D00001.
About Sapphires
Backed by KKR and Neoenta, Saphiros is a privately held consumer research company. Saphiros’ portfolio of capabilities and technologies includes novel sample collection, next-generation diagnostics, computational biology and printed electronics that help customers achieve valuable diagnostic results globally. Knowing now moves us™
For more information Sapphiros at [email protected].
About RADx
RADx® Technology/ATP programs are components of NIH’s overall RADx initiative to accelerate innovation in the development, commercialization, and implementation of technologies for COVID-19 testing. The RADx Tech/ATP innovation funnel is designed to compress traditional technology development time from years to months. This was achieved by employing teams of experts to address technical, regulatory, clinical and marketing requirements in parallel. kick off April 29, 2020RADx programs By the end of 2020, you will be able to validate, de-risk, optimize, manufacture and deploy novel tests with a seamless pipeline.
Source Sapphires
[ad_2]
Source link
